Back in September of 2010 he was also names to the Board of another technology company that deals with urology and cancer therapies. Since his tenure at the FDA it sounds like von Eschenbach is returning to his roots with using his expertise in...
Filed under: Medically Related, Pharma/FDA News, Cancer, FDA, Prostate Cancer, Pharmaceuticals, National Cancer Institute, enzymes, Durham, Viamet Pharmaceuticals, drug discovery, Andrew von Eschenbach